Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study

Membrillo de Novales et al., Preprints 2020, 2020050057, doi:10.20944/preprints202005.0057.v1
May 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 55% Improvement Relative Risk HCQ  Membrillo de Novales et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 166 patients in Spain Lower mortality with HCQ (p=0.002) c19hcq.org Membrillo de Novales et al., Preprints.., May 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
166 patients hospitalised with COVID-19, HCQ increased survival 1.4 - 1.8 times when patients admitted in early stages. Early is relative to hospital admission here - all patients were in relatively serious condition.
risk of death, 55.1% lower, RR 0.45, p = 0.002, treatment 27 of 123 (22.0%), control 21 of 43 (48.8%), NNT 3.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Membrillo de Novales et al., 5 May 2020, retrospective, Spain, preprint, 19 authors, average treatment delay 7.0 days.
This PaperHCQAll
Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
Francisco Javier Membrillo, Germán Ramírez-Olivencia, Miriam Estébanez, Begoña De Dios, María Dolores Herrero, Tatiana Mata, Alberto M Borobia, Carlos Gutiérrez, María Simón, Ana Ochoa, Yolanda Martínez, Alejandro Aguirre, Francisco De Asís Alcántara, Pablo Fernández-González, Elena López, Paula Valle, Sergio Campos, María Navarro, Lucía Elena Ballester
doi:10.20944/preprints202005.0057.v2
Hydroxychloroquine has shown in vitro activity against SARS-CoV-2. Here we present an observational study. We analysed data from 164 patients admitted to our hospital diagnosed with COVID-19. Hydroxychloroquine treatment was associated with an increase in the mean cumulative survival.
References
Bersanelli, Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors, Immunotherapy, doi:10.2217/imt-2020-0067
Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, doi:10.1056/NEJMoa2001282
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Huang, Tang, Pang, Li, Ma et al., Treating COVID-19 with Chloroquine, J Mol Cell Biol, doi:10.1093/jmcb/mjaa014
Keyaerts, Vijgen, Maes, Neyts, Ranst et al., In vitro inhibition of severe acuterespiratory syndrome coronavirus by chloroquine, Biochem Biophys Res Commun
Loutfy, Blatt, Siminovitch, Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study, JAMA, doi:10.1001/jama.290.2%204.3222
Medina Segovia, Mata, Suero, Jané, Vicente Saenz et al., Internal Medicine Department: María Jesús Sánchez Carrillo
Morgenstern, Michaelis, Baer, Doerr, Cinatl, Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines, Biochem Biophys Res Commun, doi:10.1016/j.bbrc.2004.11.128
Ramos Meca, Portales, Ángeles, Mayor, Pérez Amarilla et al., Emergency Department: Preprints
Ruiz, Coca Benito, Cano Izquierdo, Lourdes Rojas, Bueno et al., General and Digestive Surgery Department: Oscar Marqueta García
Thevarajan, Nguyen, Koutsakos, Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19, Nat Med, doi:10.1038/s41591-020-0819-2
Turner, Felton, Kosak, Kelsey, Meschievitz, Prevention of experimental coronavirus colds with intranasal alpha-2b interferon, J Infect Dis, doi:10.1093/infdis/154.3.443
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J
Wang, Xu, Gao, Lu, Han et al., Detection of SARS-CoV-2 in different types of clinical specimens, JAMA
Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
Zhang, Song, Tong, Fei, Guo et al., First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab, Blood Adv, doi:10.1182/bloodadvances.2020001907
{ 'indexed': {'date-parts': [[2024, 3, 3]], 'date-time': '2024-03-03T11:38:36Z', 'timestamp': 1709465916640}, 'posted': {'date-parts': [[2020, 5, 5]]}, 'group-title': 'MEDICINE &amp; PHARMACOLOGY', 'reference-count': 0, 'publisher': 'MDPI AG', 'license': [ { 'start': { 'date-parts': [[2020, 5, 5]], 'date-time': '2020-05-05T00:00:00Z', 'timestamp': 1588636800000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 5, 2]]}, 'abstract': '<jats:p>Background: There is no treatment proven effective against COVID-19. Several drugs ' 'with in vitro potential against SARS-CoV-2 virus have been proposed. Hydroxychloroquine has ' 'in vitro anti-viral and immunomodulatory activity, but there is no current clinical evidence ' 'of its effectiveness changing the outcome of the disease. Methods: We enrolled all 18-85 ' 'years old inpatients from Central Defense Hospital &amp;ldquo;G&amp;oacute;mez ' 'Ulla&amp;rdquo;, Madrid, Spain, who were hospitalised for COVID-19 and had a definitive ' 'outcome (dead or discharged). We used a statistical survival analysis to detect treatment ' 'differences associated with in-hospital death. Results: We analysed first 220 medical ' 'records. 166 patients met the inclusion criteria. 48,8 % of patients not treated with HCQ ' 'died, 22% of those treated with hydroxychloroquine (p=0,002). According to clinical picture ' 'at admission, hydroxychloroquine increased the mean cumulative survival in all groups from ' '1,4 to 1,8 times. This difference was statistically significant in the mild group. ' 'Conclusions: in a cohort of 166 patients from 18 to 85 years hospitalised with COVID-19, ' 'hydroxychloroquine treatment with 800mg added loading dose increased survival when patients ' 'were admitted in early stages of the disease. There was a non-statistically significant trend ' 'towards survival in all groups, which will have to be clarified in subsequent ' 'studies.</jats:p>', 'DOI': '10.20944/preprints202005.0057.v1', 'type': 'posted-content', 'created': {'date-parts': [[2020, 5, 7]], 'date-time': '2020-05-07T03:53:07Z', 'timestamp': 1588823587000}, 'source': 'Crossref', 'is-referenced-by-count': 13, 'title': 'Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An ' 'Observational Study', 'prefix': '10.20944', 'author': [ { 'given': 'Francisco Javier', 'family': 'Membrillo de Novales', 'sequence': 'first', 'affiliation': []}, {'given': 'Germán', 'family': 'Ramírez-Olivencia', 'sequence': 'additional', 'affiliation': []}, {'given': 'Miriam', 'family': 'Estébanez', 'sequence': 'additional', 'affiliation': []}, {'given': 'Begoña', 'family': 'de Dios', 'sequence': 'additional', 'affiliation': []}, {'given': 'María Dolores', 'family': 'Herrero', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tatiana', 'family': 'Mata', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alberto M.', 'family': 'Borobia', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carlos', 'family': 'Gutiérrez', 'sequence': 'additional', 'affiliation': []}, {'given': 'María', 'family': 'Simón', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ana', 'family': 'Ochoa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yolanda', 'family': 'Martínez', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alejandro', 'family': 'Aguirre', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Francisco de Asís', 'family': 'Alcántara', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pablo', 'family': 'Fernández-González', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elena', 'family': 'López', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sergio', 'family': 'Campos', 'sequence': 'additional', 'affiliation': []}, {'given': 'María', 'family': 'Navarro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lucía Elena', 'family': 'Ballester', 'sequence': 'additional', 'affiliation': []}], 'member': '1968', 'container-title': [], 'original-title': [], 'deposited': { 'date-parts': [[2020, 5, 11]], 'date-time': '2020-05-11T10:44:34Z', 'timestamp': 1589193874000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.preprints.org/manuscript/202005.0057/v1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 5, 5]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.20944/preprints202005.0057.v1', 'relation': { 'is-version-of': [ { 'id-type': 'doi', 'id': '10.20944/preprints202005.0057.v2', 'asserted-by': 'subject'}], 'has-version': [ { 'id-type': 'doi', 'id': '10.20944/preprints202005.0057.v2', 'asserted-by': 'object'}]}, 'published': {'date-parts': [[2020, 5, 5]]}, 'subtype': 'preprint'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit